495 related articles for article (PubMed ID: 26285137)
1. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
[TBL] [Abstract][Full Text] [Related]
2. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
3. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
5. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
[TBL] [Abstract][Full Text] [Related]
11. Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.
La Salvia A; Rossi A; Galetta D; Gobbini E; De Luca E; Novello S; Di Maio M
Clin Lung Cancer; 2017 Jan; 18(1):23-33.e1. PubMed ID: 27876230
[TBL] [Abstract][Full Text] [Related]
12. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang TT; Wang RM; Yang Z; Chen GB
Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
Liu J; Sheng Z; Zhang Y; Li G
Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials.
Li G; Gao S; Sheng Z; Li B
Chemotherapy; 2016; 61(4):179-89. PubMed ID: 26859739
[TBL] [Abstract][Full Text] [Related]
17. EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
Zhu CM; Lian XY; Zhang HY; Bai L; Yun WJ; Zhao RH; Li QS
J Cancer Res Ther; 2021 Jul; 17(3):664-670. PubMed ID: 34269297
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang M; Guo H; Zhao S; Wang Y; Yang M; Yu J; Yan Y; Wang Y
Oncotarget; 2016 Jun; 7(26):39823-39833. PubMed ID: 27223081
[TBL] [Abstract][Full Text] [Related]
20. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Xu R; Shao H; Zhu J; Ju Q; Shi H
Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
